Dr.Reddy’s Laboratories (RDY) to Release Quarterly Earnings on Friday

Dr.Reddy’s Laboratories (NYSE:RDY) is scheduled to issue its quarterly earnings data before the market opens on Friday, May 17th.

Shares of NYSE RDY opened at $41.86 on Friday. The company has a market capitalization of $6.95 billion, a price-to-earnings ratio of 41.45 and a beta of 0.13. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.26 and a current ratio of 1.81. Dr.Reddy’s Laboratories has a 52-week low of $28.13 and a 52-week high of $42.82.

RDY has been the topic of a number of research analyst reports. TheStreet raised Dr.Reddy’s Laboratories from a “c+” rating to a “b” rating in a research report on Friday, February 1st. Zacks Investment Research upgraded shares of Dr.Reddy’s Laboratories from a “hold” rating to a “buy” rating and set a $44.00 price target for the company in a research note on Tuesday, March 19th. CL King upgraded shares of Dr.Reddy’s Laboratories from a “neutral” rating to a “buy” rating in a research note on Monday, February 4th. Finally, Citigroup downgraded shares of Dr.Reddy’s Laboratories from a “neutral” rating to a “sell” rating in a research note on Thursday, January 17th. One analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company. The company presently has an average rating of “Hold” and an average target price of $44.00.

COPYRIGHT VIOLATION WARNING: “Dr.Reddy’s Laboratories (RDY) to Release Quarterly Earnings on Friday” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2019/05/10/dr-reddys-laboratories-rdy-to-release-quarterly-earnings-on-friday.html.

Dr.Reddy’s Laboratories Company Profile

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

Read More: What is a Tariff?

Earnings History for Dr.Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply